Introduction {#S1}
============

*Pseudomonas aeruginosa*, a versatile and ubiquitous Gram-negative bacterium, is an opportunistic microorganism that frequently causes severe nosocomial infections, particularly among immunocompromised patients and those suffering from cystic fibrosis, burns, HIV infection, and cancer ([@B67]; [@B56]; [@B62]; [@B37]; [@B75]). The pathogenicity of *P. aeruginosa* is attributable mainly, if not solely, to the regulons of two complete *N*-acyl homoserine lactone (AHL)-dependent quorum sensing (QS) systems, called LasI/R and RhlI/R ([@B49]; [@B73]). The two QS systems act in a hierarchical manner, i.e., the lasI/R system controls the activity of the rhlI/R circuit ([@B45], [@B46]). During bacterial infection, the LasI and RhlI synthases produce *N*-(3-oxododecanoyl)-*L*-homoserine lactone (3O-C12-HSL) and *N*-butanoyl-*L*-homoserine lactone (C4-HSL), respectively. The QS molecules then interact with their cognate LasR and RhlR, causing transcription of hundreds of target genes, including those coding for virulence factors such as lectins, elastases, proteases, exotoxin A, pyocyanin, and surface-active rhamnolipids important in the late stages of biofilm development, as well as genes involved in antibiotic resistance ([@B74]; [@B73]; [@B55]; [@B39]).

*N*-(3-Oxododecanoyl)-*L*-homoserine lactone (3O-C12-HSL) is the prominent autoinducer of the *P. aeruginosa* QS system ([@B9]; [@B50]). 3O-C12-HSL is a small, fatty acid-like, membrane-permeant signaling molecule that comprises a hydrophilic homoserine lactone ring linked to the hydrophobic 12-carbon-atom-long acyl side chain via an amide bond ([@B10]; [@B46]; [@B54]; [@B42]). The roles of 3O-C12-HSL in pathogenesis and modulation of the host immune responses have been reviewed ([@B34]). Owing to its lipophilicity, the 3O-C12-HSL can traverse the mammalian cell membrane ([@B54]), causing mitochondrial damage and dysfunction, which subsequently activates the caspase pathway leading to apoptosis of several cell types, including macrophages, neutrophils, T lymphocytes, human vascular endothelial cells, murine fibroblasts, airway epithelial cells, goblet cells, and breast carcinoma cells ([@B71]; [@B33]; [@B60]; [@B20]; [@B59]; [@B68], [@B69]). *P. aeruginosa* QS signaling molecules also modulate host immune responses by down-regulating the expression of co-stimulatory molecules on dendritic cells (DCs), leading to inhibition of DC maturation and their ability to activate effector T-cell responses ([@B4]). Because the 3O-C12-HSL plays an important role in the virulence and pathogenesis of *P. aeruginosa* and host immunity suppression, it is an attractive target for novel therapeutics for *P. aeruginosa* infection. Substances that interfere with *P. aeruginosa* 3O-C12-HSL activity should mitigate bacterial-associated disease severity, although blocking the QS system alone does not necessarily abrogate all *P. aeruginosa* virulence factors, such as T3SS ([@B3]; [@B35]; [@B65]). A therapeutic approach based on QS interference and/or attenuation of QS signals should result in greater sensitivity of the *P. aeruginosa* to stresses, such as antimicrobial drugs ([@B51]; [@B8]; [@B36]; [@B23]; [@B30]).

Recently, a murine monoclonal antibody (mAb), RS2-1G9, against a lactam mimetic of 3O-C12-HSL has been shown to prevent apoptosis through p38 mitogen-activated protein kinase activation and protected murine bone marrow-derived macrophages from the cytotoxic effects of the QS molecule ([@B25], [@B24]). The RS2-1G9 paratope was shown to enclose the polar lactam moiety of the 3O-C12-HSL molecule in the co-crystal structure of the Fab fragment of the RS2-1G9 mAb and the target 3O-C12-HSL completely ([@B7]). Active immunization of mice with 3O-C12-HSL-protein conjugate protected immunized mice from lethal *P. aeruginosa* infection ([@B38]). Antibody-based therapy directed to the QS molecule should not only block bacterial virulence, but also rescue the host immunity that had been modulated/suppressed by the QS system ([@B24]; [@B43]). The present study generated engineered, fully human, single-chain antibody variable fragments (HuscFvs) that neutralize 3O-C12-HSL bioactivity. The HuscFvs should be tested, step-by-step, toward clinical application as a sole or adjunct therapy for the currently failing antibiotic treatment of patients with *P. aeruginosa* infection.

Materials and Methods {#S2}
=====================

*P. aeruginosa N*-(3-Oxododecanoyl)-*L*-Homoserine Lactone (3O-C12-HSL) {#S2.SS1}
-----------------------------------------------------------------------

The QS molecule was synthesized commercially (Cayman Chemical, Ann Arbor, MI, United States) under the IUPAC name: 3-oxo-*N*-\[(3*S*)-2-oxooxolan-3-yl\]-dodecanamide. 3O-C12-HSL was stored in 100% dimethyl-sulfoxide (DMSO) and diluted with phosphate-buffered saline, pH 7.4 (PBS), to the desired concentration for use.

Preparation of HuscFv to *P. aeruginosa* 3O-C12-HSL {#S2.SS2}
---------------------------------------------------

The human single-chain variable fragments (HuscFvs) to the 3O-C12-HSL were generated based on the principles of the polyspecific property of an antibody, i.e., one antibody can bind different antigens by paratope adaptation to accommodate distinct antigens, such as through differential engagements of the complementarity determining regions (CDRs), and the molecular mimicry of the antigens (different antigens can share surface topologies in terms of shape or chemical nature) ([@B70]). In this study, HB2151 *Escherichia coli* clones carrying phagemids with inserted HuscFv genes (*huscfvs*) were previously selected from a HuscFv phage display library ([@B31]) using *Pseudomonas* exotoxin A (ETA) as antigen in the phage-biopanning process ([@B57]). Genes coding for HuscFvs of individual *E. coli* clones were sequenced and deduced, and the canonical CDRs and framework regions (FRs) of both VH and VL domains were determined based on the numbering scheme of Chotia and Kobat ([@B1]).

Three dimensional (3D) models of the selected HuscFvs were generated by subjecting their deduced amino acid sequences to the I-TASSER online server ([@B79]). The HuscFvs-3D models from the I-TASSER were further refined to improve local geometric and physical quality using ModRefiner ([@B78]). The quality of the generated homology models of HuscFvs was then evaluated using the PROCHECK server to provide Ramachandran plots ([@B32]). Thereafter, the 3D structures of the individual HuscFvs were superimposed with the 3D structure of the mAb RS2-1G9 F(ab′)~2~ (PDB ID: 2NTF) (previously shown to neutralize 3O-C12-HSL pathogenic activity; hence, the mAb has been designated as a "quorum quenching antibody") ([@B25], [@B24]) using the CLICK server, i.e., the topology-independent tool comparing 3D structures without a scoring function measuring structural similarity ([@B40]). The HuscFvs showing top-scored topological similarity with the RS2-1G9 antigen-binding site were selected. The 3D structure of 3O-C12-HSL was retrieved from the PubChem database, a resource of chemical molecules and their bioactivities (PubChem CID: 3246941) ([@B28]). The modeled-3O-C12-HSL F(ab′)~2~ was docked with the 3D model of each HuscFv receptor binding pocket using Autodock Vina software ([@B72]; [@B13]). The conformation of each HuscFv-ligand complex with the lowest binding free energy (ΔG) at the best docking position was selected for interaction analysis and visualization through the Discovery studio visualizer 3.5 program.

Large-Scale Production of HuscFvs {#S2.SS3}
---------------------------------

The *E. coli* clones carrying phagemids containing the DNA coding for the selected HuscFvs were subjected to sub-cloning for large scale HuscFv production. The *huscfvs* were PCR-amplified from the *huscfv*-pCANTAB5E phagemids of HB2151 *E. coli* clones using a Phusion High-Fidelity DNA polymerase (Thermo Fisher Scientific, Carlsbad, CA, United States). The PCR specific primers were forward-*huscfv*-LIC: 5′-GGTTGGGAATTGCAAGCGGC CCAGCCGGCC-3′ and reverse-*E-tag*-LIC: 5′-GGAGATGGGA AGTCATTAACGCGGTTCCAGCGGATCC-3′. The *huscfv* inserts were designed to consist of a HuscFv-coding sequence linked to specific sequences for ligation independent cloning (LIC) protocol (Thermo Fisher Scientific). The amplified *huscfv-E-tag* DNAs were cloned separately into the pLATE52 vector (Thermo Fisher Scientific). Recombinant pLATE52-*huscfv* plasmids were transformed into JM109 *E. coli* by the heat-shock method. After PCR screening and DNA sequencing, the recombinant plasmids were introduced into an expression host, NiCo21(DE3) *E. coli* (New England Biolabs, St. Albans, Herts, United Kingdom), and the transformed bacteria were grown at 37°C for 16 h on LB agar containing 100 μg/ml of ampicillin. A single colony of each transformed clone was cultured in LB broth containing 100 μg/ml ampicillin with shaking (250 rpm) at 37°C for 16 h. The overnight cultures (12.5 ml) were separately inoculated into the fresh LB medium (250 ml) containing ampicillin and grown at 37°C until an OD~600\ nm~ reached ∼0.6--0.8. Recombinant HuscFv expression was induced by adding isopropyl-β*-D*-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM and incubated at 30°C for 6 h. The bacterial pellets were collected by centrifugation at 5,000 × *g* at 4°C for 20 min.

The recombinant HuscFvs were purified from the bacterial inclusion bodies (IBs) as described previously ([@B22]). Two grams of *E. coli* wet cell pellets were resuspended in 10 ml of BugBuster^TM^ protein extraction reagent (Novagen, Schwalbach, Germany) and 20 μl of Lysonase^TM^ bioprocessing reagent (Novagen) were added to each preparation. The preparations were kept at 25°C on a rotator for 20 min and cell pellets were collected after centrifugation at 8,000 × *g* at 4°C for 30 min. The IBs were washed with Wash-100 reagent \[50 mM sodium phosphate buffer, pH 8.0; 500 mM NaCl; 5 mM EDTA; 8% (w/v) glycerol; and 1% (v/v) Triton X-100\] twice and once with Wash-114 buffer \[50 mM Tris--HCl, pH 8.0; 300 mM NaCl; and 1% (v/v) Triton X-114\] with shaking at high speed for 40 min, and the IB pellets were then collected. The IBs were then washed with Wash-Solvent solution \[50 mM Tris--HCl, pH 8.0; and 60% (v/v) isopropanol\] and sterile ultrapure distilled water on ice, also with vigorous shaking, and centrifuged. Thereafter, 2.5 mg of purified IB pellets were solubilized in 5 ml of solubilizing buffer \[50 mM CAPS, pH 11.0; 0.3% (w/v) *N*-lauryl sarcosine; and 1 mM dithiothreitol (DTT)\] and kept at 4°C for 16 h. After dissolving completely, the protein was loaded into Snakeskin dialysis tubing with a molecular weight cut-off of 10 kDa (Thermo Fisher Scientific), and dialyzed against 750 ml of refolding buffer (20 mM imidazole, pH 8.5, supplemented with 0.1 mM DTT) at 4°C with slow stirring. After 3 h, the buffer was changed to a fresh refolding buffer, and dialysis was continued for 16 h. The refolded protein was subsequently dialyzed against a dialysis buffer without DTT with slow stirring at 4°C for 16 h. Each preparation was filtered through a 0.2-μm low protein binding Acrodisc^®^ Syringe Filter (Pall, Port Washington, NY, United States) and kept at 30°C in a water bath for 3 h before adding 60 mM trehalose. The protein concentration of the refolded HuscFvs was determined using Pierce^®^ BCA Protein Assay, while the quality and purity of the recombinant proteins were analyzed by SDS-PAGE and stained with Coomassie Brilliant Blue G-250 (Bio-rad, Hercules, CA, United States). Refolded HuscFv preparations were concentrated using Amicon^®^ Ultra 4 ml 3K centrifugal filter devices (Merck Millipore, Darmstadt, Germany) and stored at −20°C until use.

Circular Dichroism {#S2.SS4}
------------------

The buffer of the HuscFv preparations was changed to 20 mM sodium phosphate buffer, pH 8.5, at a protein concentration of 0.1 mg/ml, and the antibodies were subjected to CD measurement. The data were recorded using a JASCO spectrometer (model J-815) equipped with a Peltier temperature controller system (Jasco, Tokyo, Japan) in a 1 mm path-length quartz cuvette. The proteins were scanned at 50 nm/min at 25°C. The CD spectra were collected over a wavelength range of 190--260 nm.

Cell Line {#S2.SS5}
---------

Human cervical carcinoma, HeLa, cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Gibco, Carlsbad, CA, United States) supplemented with 10% (v/v) fetal bovine serum (Hyclone, Novato, CA, United States) and 1% (v/v) penicillin-streptomycin (complete DMEM) at 37°C in a 5% CO~2~ atmosphere.

Determination of the Biocompatibility of the HuscFvs to Mammalian Cells {#S2.SS6}
-----------------------------------------------------------------------

The monolayer of HeLa cells established in individual wells of a 24-well tissue culture plate (∼2 × 10^5^ cells/well) were washed with sterile PBS, added with 2 μM of individual HuscFv preparations in complete DMEM, and incubated at 37°C in 5% CO~2~ atmosphere for 24 h. Cells in the medium alone served as a background control. After 24 h, the percent viability of cells of each treatment was analyzed using an FITC-Annexin V Apoptosis Detection Kit (BD Biosciences, San Jose, CA, United States) according to the manufacturer's protocols. The cells were washed with Dulbecco's phosphate-buffered saline (DPBS) and resuspended in binding buffer. Five microliters of Annexin V-FITC conjugate and 5 μl of propidium iodide (PI) were added. After 15-min incubation at room temperature (25°C) in darkness, apoptotic cells were enumerated by flow cytometric analysis (BD LSRFortessa^TM^, San Jose, CA, United States) using BD FACSDiva^TM^ software (BD Biosciences). At least 20,000 events of single cells per sample were collected.

Cellular Apoptosis Mediated by 3O-C12-HSL {#S2.SS7}
-----------------------------------------

HeLa cells (∼2 × 10^5^ cells/well) were treated with various concentrations of 3O-C12-HSL, i.e., 10, 25, 50, 75, and 100 μM. The background control comprised of cells incubated with medium alone. After incubation at 37°C in a CO~2~ incubator for 18 h, the cells were harvested and subjected to Annexin V/PI binding assay, as described above.

Neutralization of 3O-C12-HSL-mediated-Cytotoxicity by HuscFvs {#S2.SS8}
-------------------------------------------------------------

Fifty micromolars of 3O-C12-HSL in 0.25% DMSO were mixed with various concentrations of individual HuscFv preparations (0.25, 0.5, 1.0, and 1.2 μM) for 1 h before adding to HeLa cells (∼2 × 10^5^ cells/well) and incubated at 37°C in a CO~2~ incubator for 18 h. After incubation, the cells were collected, washed, double-stained with Annexin V-FITC and PI, and analyzed by flow cytometry, as described above. Three independent experiments were performed.

Neutralization of 3O-C12-HSL-mediated Cell Cycle Arrest by HuscFvs {#S2.SS9}
------------------------------------------------------------------

HeLa cells (∼2 × 10^5^ cells/well) were treated with a mixture of 50 μM 3O-C12-HSL and 1 μM of individual HuscFvs for 18 h. HeLa cells exposed to medium alone served as a control. After incubation, cells were washed with ice-cold PBS, fixed in 70% ethanol, and kept at −20°C overnight. Cells were then washed 3 times with ice-cold PBS and incubated in 500 μl of stain solution \[10 μg/ml PI, 100 μg/ml RNase, and 0.1% (v/v) Triton X-100 in DPBS, pH 7.4\] at room temperature in darkness for 30 min. The DNA contents of the cells were measured, and cell cycle histograms/distributions were generated. Then, the percentage of cells in the sub-G1 phase was determined by flow cytometry (BD LSRFortessa^TM^) using BD FACSDiva^TM^ software (BD Biosciences), with at least 10,000 recorded events per sample.

Analysis of Nuclear Damage by Fluorescence Staining {#S2.SS10}
---------------------------------------------------

Nuclear damage was studied using 4',6-diamidino-2-phenylindole (DAPI) staining. Briefly, HeLa cells (1 × 10^6^ cells) were seeded on a 22 × 22 mm square coverslip (Menzel-Glaser, Braunschweig, Germany) in a 6-well plate (Costar, New York, NY, United States) and kept at 37°C in a 5% CO~2~ incubator for 24 h. The culture medium was removed and the cells were replenished with complete DMEM containing a mixture of 3O-C12-HSL (50 μM) and HuscFvs (2 μM). After 18 h, the cells were washed and fixed with 4% (v/v) paraformaldehyde in PBS, permeabilized with 1% (v/v) Triton X-100 in PBS, blocked with 3% (w/v) bovine serum albumin (BSA) in PBS at room temperature for 30 min, then washed. The permeabilized cells were stained and mounted with DAPI (1:5,000) (Molecular Probes, Carlsbad, CA, United States) in the anti-fade mounting medium. DNA fragmentation and chromatin condensation were observed under a confocal microscope (Carl Zeiss Laser Scanning System LSM 700, Jena, Germany). Images were processed using the Zeiss LSM Image Browser (version 6.0.0.309).

Transmission Electron Microscopy {#S2.SS11}
--------------------------------

Transmission electron microscopy (TEM) was used to examine the ultrastructural changes of the HeLa cell mitochondria after various treatments. The cells from each treatment group were fixed with 2.5% (v/v) glutaraldehyde in 0.1 M sucrose phosphate buffer (SPB) at room temperature for 1 h, washed three times with 0.1 M SPB, post-fixed with 1.0% (w/v) osmium tetroxide in the same buffer for 1 h, and dehydrated with a graded series of ethanol. The dehydrated cells were infiltrated with pure LR white embedded medium (EMS^®^, Hatfield, PA, United States) in 70% (v/v) ethanol, embedded in a capsule beam, and incubated at 65°C for 48 h. The ultrathin (100 nm) sections of the cells were prepared; the sections were positioned on a 200 square-mesh copper grid and stained with ethanolic uranyl acetate and lead citrate. The morphological and structural characteristics of mitochondria were observed under a transmission electron microscope (model HT7700, Hitachi, Tokyo, Japan).

Statistical Analysis {#S2.SS12}
--------------------

Statistical analyses of all experiments were performed using GraphPad Prism 5 software (La Jolla, CA, United States). One-way ANOVA followed by Tukey's *post hoc* multiple comparison tests were used to analyze the differences between groups. All data are shown as mean ± SD. Statistically significant difference was set at *p* \< 0.05.

Results {#S3}
=======

HuscFvs to 3O-C12-HSL {#S3.SS1}
---------------------

The refined models of HuscFvs for the selected HB2151 *E. coli* clones derived from phage biopanning with *P. aeruginosa* exotoxin A revealed that HuscFvs of three *E. coli* clones, i.e., E44 (HuscFv-E44), F15 (HuscFv-F15), and F19 (HuscFv-F19), showed reliable Ramachandran plots. The percent residues in the most favored regions, the additional allowed regions, the generously allowed regions, and the disallowed regions of the Ramachandran diagrams of the HuscFv-E44, HuscFv-F15, and HuscFv-F19 were 90.1, 6.8, 1.0, and 2.1 %; 91.3, 7.7, 0.5, and 0.5%; and 88.2, 9.4, 1.0, and 1.5%, respectively ([Supplementary Figure S1](#DS1){ref-type="supplementary-material"}).

From structural comparisons of individual HuscFvs with the antigen-binding site of the well-characterized quorum quenching mAb, i.e., RS2-1G9 (shown previously to bind to and neutralize the activities of *P. aeruginosa* 3O-C12-HSL), it was found that the binding pockets of the three HuscFvs were superimposed with the antigen-binding site of RS2-1G9. The coverage percentages of the overlapping structures between the modeled HuscFv-E44, HuscFv-F15, and HuscFv-F19 and the RS2-1G9 were 90.83, 89.29, and 88.58%, respectively ([Figure 1](#F1){ref-type="fig"} and [Supplementary Table S1](#DS1){ref-type="supplementary-material"}).

![The 3D complex of RS2-1G9 F(ab′)~2~ fragment and *N*-Acyl-*L*-homoserine lactone analog (PDB:2NTF) was superimposed by the HuscFv-E44 (left), HuscFv-F15 (middle), and HuscFv-F19 (right) using CLICK: <http://mspc.bii.a-star.edu.sg/click> **(Upper panel)**. One antigen-binding site of the mAb RS2-1G9 F(ab′)~2~ fragment (VH and VL domains, shown in blue) was superimposed by the HuscFvs (green). The trace illustration is the remaining portion of the RS2-1G9 F(ab′)~2~. **Lower panel**, the superimposed amino acids of the RS2-1G9 antigen-binding site (2NTF) and the VH and VL of HuscFv-E44, HuscFv-F15, and HuscFv-F19, are shown in red alphabets.](fmicb-11-01172-g001){#F1}

Homology Modeling and Intermolecular Docking Between HuscFvs and 3O-C12-HSL {#S3.SS2}
---------------------------------------------------------------------------

*In silico* intermolecular docking was performed to investigate the interaction of the HuscFvs with the 3O-C12-HSL. The residues of HuscFv-E44, HuscFv-F15, and HuscFv-F19 that tentatively formed interactive bonds with the haptenic 3O-C12-HSL target are shown in [Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}. The Gibbs free energy (ΔG) of the representative complexes of respective HuscFvs with the ligand were −5.6, −5.8, and −5.4 kcal/mol, respectively.

![Computerized contact interfaces between 3O-C12-HSL and HuscFvs. **(A--C)** on the left side of the panels show interaction between 3D structures of 3O-C12-HSL (yellow stick) and green ribbons of **(A)** HuscFv-E44, **(B)** HuscFv-F15, **(C)** HuscFv-F19. Right side of the panels **(A--C)** show residues of the respective HuscFvs and the HuscFv-3O-C12-HSL interactive bonds (yellow, hydrogen bond; light pink, alkyl; magenta, Pi-alkyl; green, van der Waals force).](fmicb-11-01172-g002){#F2}

###### 

Residues of *Pseudomonas aeruginosa* 3O-C12-HSL predicted to form contact interfaces with the effective HuscFv-E44, HuscFv-F15, and HuscFv-F19.

  -------------------------------------------------------------------------------------------
  3O-C12-HSL position        HuscFv-E44       Interactive bond       
  -------------------------- ---------------- ---------------------- ------------------------
  Ketone group of HSL ring   E46              VH-FR2                 Van de Waals

  C3 of HSL ring             G44\             VH-FR2\                Van de Waals\
                             G232             VL-FR4                 Van de Waals

  C4 of HSL ring             G44              VH-FR2                 Van de Waals

  NH-group                   L45\             VH-FR2\                Hydrogen\
                             E46\             VH-FR2\                Van de Waals\
                             F231             VL-FR4                 Van de Waals

  1-oxo-group                T230\            VL-CDR3\               Van de Waals\
                             F231             VL-FR4                 Van de Waals

  C2 of acyl chain           E46\             VH-FR2\                Van de Waals\
                             T230             VL-CDR3                Van de Waals

  3-oxo-group                W47\             VH-FR2\                Hydrogen\
                             N60              VH-CDR2                Hydrogen

                             E46\             VH-FR2\                Van de Waals\
                             Y229             VL-CDR3                Van de Waals

  C5 of acyl chain           E133             VL-FR1                 Van de Waals

  C9 of acyl chain           S62              VH-CDR2                Van de Waals

  C10, C11 of acyl chain     R38\             VH-FR2\                Van de Waals\
                             R66              VH-FR3                 Van de Waals

  C12 of acyl side chain     L63              VH-CDR2                Hydrophobic (alkyl)

  C12 of acyl side chain     R38\             VH-FR2\                Van de Waals\
                             R66\             VH-FR3\                Van de Waals\
                             N89              VH-FR3                 Van de Waals

                                                                     

  **3O-C12-HSL position**    **HuscFv-F15**   **Interactive bond**   

                             **Residue(s)**   **Domain**             

                                                                     

  C3 of HSL ring             P62              VH-CDR2                Van de Waals

  C3, C4 of HSL ring         D140             VL-FR1                 Van de Waals

  1-oxo-group                W47\             VH-FR2\                Van de Waals\
                             S61              VH-CDR2                Van de Waals

                             S63              VH-CDR2                Hydrogen

  C2 of acyl chain           W47/A241         VH-FR2                 Van de Waals

  3-oxo-group                P240/A241/T242   VL-CDR3                Van de Waals

                             W47\             VH-FR2\                Van de Waals\
                             A241             VL-CDR3                Van de Waals

  C4 of acyl chain           W4\              VH-FR2\                Van de Waals\
                             F243             VL-FR4                 Van de Waals

                             A241/T242        VL-CDR3                Van de Waals

  C5 of acyl chain           E46, W47\        VH-FR2\                Van de Waals\
                             F243             VL-FR4                 Van de Waals

  C6 of acyl chain           F243             VL-FR4                 Van de Waals

  C7 of acyl chain           L45, E46\        VH-FR2\                Van de Waals\
                             F243             VL-FR4                 Van de Waals

  C8 of acyl chain           K43, E46         VH-FR2                 Van de Waals

  C9 of acyl chain           K43              VH-FR2                 Van de Waals

                             F243/G244/Q245   VL-FR4                 Van de Waals

  C10 of acyl chain          F243/G244/Q245   VL-FR4                 Van de Waals

  C12 of acyl chain          V142             VL-FR1                 Hydrophobic (alkyl)

                             M143\            VL-FR1\                Van de Waals\
                             T242\            VL-CDR3\               Van de Waals\
                             F243             VL-FR4                 Van de Waals

                                                                     

  **3O-C12-HSL position**    **HuscFv-F19**   **Interactive bond**   

                             **Residue(s)**   **Domain**             

                                                                     

  Ketone group of HSL ring   R38\             VH-FR2\                Van de Waals\
                             E89              VH-FR3                 Van de Waals

  C3, C4 of HSL ring         K43              VH-FR2                 Van de Waals

  Oxygen of HSL ring         E89              VH-FR3                 Van de Waals

  NH-group                   R38, E46         VH-FR2                 Hydrogen

  1-oxo-group                R38              VH-FR2                 Van de Waals

                             S63\             VH-CDR2\               Hydrogen\
                             G139             Linker                 Hydrogen

  C2 of acyl side chain      R38              VH-FR2                 Van de Waals

  C7, C8 of acyl chain       L45\             VH-FR2\                Van de Waals\
                             F245             VL-FR4                 Van de Waals

  C9 of acyl side chain      T244\            VL-CDR3\               Van de Waals\
                             F245             VL-FR4                 Van de Waals

  C10 of acyl chain          E148             VL-FR1                 Van de Waals

  C11 of acyl chain          L243             VL-CDR3                Van de Waals

  C12 of acyl chain          W47\             VH-FR2\                Hydrophobic (π-alkyl)\
                             A61\             VH-CDR2\               Hydrophobic (alkyl)\
                             P242             VL-CDR3                Hydrophobic (alkyl)
  -------------------------------------------------------------------------------------------

The HuscFv-E44 used residues from VH-CDR2 and VL-CDR3, as well as help from VH-FR2, VH-FR3, VL-FR1, and VL-FR4 to form contact interfaces with the functional groups of 3O-C12-HSL. The interactions were three hydrogen bonds between L45 of VH-FR2 with the NH group of the coordinated 3O-C12-HSL (2.18 Å) and N60 of VH-CDR2, and W47 of VH-FR2 with the 3O-C12-HSL carbonyl oxygen of 3-oxo-group of the acyl chain (2.97 and 2.44 Å, respectively). There was one hydrophobic interaction (alkyl) formed between L63 of VH-CDR2 and C12 of the acyl chain of AHL. HuscFv-E44 also used many residues in different domains to form contact interfaces via van der Waals forces with the 3O-C12-HSL, including S62 of VH-CDR2; Y229 and T230 of VL-CDR3; R38, G44, and E46 of VH-FR2; R66 and D89 of VH-FR3, E133 of VL-FR1; and F231, G232, and Q233 of VL-FR4 ([Table 1](#T1){ref-type="table"}).

HuscFv-F15 formed a hydrogen bond (2.25 Å) with the carbonyl oxygen of the 1-oxo-group of the fatty acid-like ligand through S63 of VH-CDR2. This antibody also used V142 of VL-FR1 to form hydrophobic contact (alkyl) with the C12 of the hapten acyl chain. Several other positions of the 3O-C12-HSL molecule have interacted via van der Waals forces with several residues of the HuscFv-F15 including S61 and P62 of VH-CDR2; P240, A241, and T242 of VL-CDR3; K43, L45, E46, and W47 of VH-FR2; D140 and M143 of VL-FR1; and F243, G244, and Q245 of VL-FR4.

Serine 63 of VH-CDR2 and G139 of the HuscFv-F19 linker formed contact with the carbonyl oxygen of the 1-oxo-group of the 3O-C12-HSL via hydrogen bonds (2.06 and 2.44 Å, respectively). Hydrogen bonding also occurred between E46 of VH-FR2 and the NH-group of the HSL backbone (2.07 Å). The last carbon atom of the long acyl side chain of the 3O-C12-HSL formed π-alkyl hydrophobic interaction with W47 of VH-FR2 as well as the alkyl hydrophobic interaction with A61 of VH-CDR2 and P242 of VL-CDR3. In addition, the HuscFv-F19 formed van der Waals contacts with the 3O-C12-HSL by using L243 and T244 of VL-CDR3; R38, K43, and L45 of VH-FR2; E89 of VH-FR3; E148 of VL-FR1; and F245 of VL-FR4.

The results of the structural comparison of the HuscFvs with the quorum quenching mAb, RS2-1G9, and the intermolecular docking between the HuscFvs and the 3O-C12-HSL enticed us to test further the ability of HuscFvs to neutralize *P. aeruginosa* 3O-C12-HSL activities.

Large-Scale Production of HuscFvs {#S3.SS3}
---------------------------------

The *huscfv* inserts in the pCANTAB5E phagemids of the *E. coli* clones E44, F15, and F19 were sub-cloned into the pLATE52 vector. The DNA construct in the vector is shown in [Figure 3A](#F3){ref-type="fig"}. The amplicon of DNA coding for 6 × His tagged-HuscFv formed a PCR amplicon band at ∼ 850 bp, as revealed on agarose gel ([Figure 3B](#F3){ref-type="fig"}). The refolded and purified HuscFv-E44, HuscFv-F15, and HuscFv-F19, with molecular sizes of about 34 kDa, are shown in [Figure 3C](#F3){ref-type="fig"}.

![Production and characterization of HuscFvs to 3O-C12-HSL. **(A)** Schematic diagram of the inserted DNA construct in pLATE52 where the DNA sequence coding for HuscFv (*vh-linker-vl*) was flanked with DNA sequences of 6 × His at the 5′ end and E-tag at the 3′ end. **(B)** Amplicons of *huscfv*-LIC fragments (∼ 850 bp) for sub-cloning into pLATE52 vector. M, 100 bp-plus DNA ladder; 1--3, *huscfv*-LIC amplicons of three representatives transformed NiCo21(DE3) *E. coli* clones. Numbers at the left are DNA sizes in bp. **(C)** Stained SDS-PAGE-separated purified recombinant HuscFvs. M, protein standard; 1--3, purified HuscFv-E44, HuscFv-F15 and HuscFv-F19, respectively. Numbers at the left are protein masses in kDa. **(D)** CD spectra of the refolded HuscFv-E44, HuscFv-F15, and HuscFv-F19.](fmicb-11-01172-g003){#F3}

Secondary structures of the refolded HuscFvs were determined by far-UV CD spectroscopy. The far-UV CD spectra (190--260 nm) for all HuscFvs revealed their β-sheet structures, which shared a similar CD spectra pattern ([Figure 3D](#F3){ref-type="fig"}). The antibody preparations did not form aggregates.

Biocompatibility of HuscFvs to Mammalian Cells {#S3.SS4}
----------------------------------------------

HeLa cells exposed to 2 μM of HuscFv-E44, HuscFv-F15, and HuscFv-F19 for 24 h showed more than 90% viability, which was not different from the cells in medium alone (*p* \> 0.05) ([Supplementary Figure S2](#DS1){ref-type="supplementary-material"}) indicating biocompatibility of the HuscFvs to the representative mammalian cells.

HuscFvs-bound 3O-C12-HSL Had Impairment in Inducing Mammalian Cell Apoptosis {#S3.SS5}
----------------------------------------------------------------------------

The average percentages of apoptotic HeLa cells treated with 10, 25, 50, 75, and 100 μM of 3O-C12-HSL dissolved in 0.25% DMSO, from three independent experiments, were 6.67 ± 0.53, 10.08 ± 1.41, 20.85 ± 1.62, 36.37 ± 2.32, and 49.63 ± 2.51%, respectively, while the background apoptotic cells of the control (cells in culture medium) was 5.71 ± 0.59% ([Figure 4A](#F4){ref-type="fig"}). [Figure 4B](#F4){ref-type="fig"} shows the results of the flow cytometric analysis of apoptotic cells (stained with Annexin V/PI) from one representative experiment. The background apoptotic cells (% cell viability) with and without 0.25% DMSO in the culture medium were not different ([Supplementary Figure S3](#DS1){ref-type="supplementary-material"}).

![The percentages of apoptotic HeLa cells exposed to different concentrations of 3O-C12-HSL. **(A)** Bar graph of average percentages (means ± SD) of apoptotic cells from three independent experiments after exposure to 10, 25, 50, 75, and 100 μM of C12-HSL, compared with the cells in medium alone. **(B)** The density plots of HeLa cells after treatment with 10, 25, 50, 75, and 100 μM of C12-HSL, and control cells stained by Annexin V-FITC/PI and subjected to flow cytometric analysis (representative of three independent experiments). The cytotoxic activity of the 3O-C12-HSL was dose-dependent. Q1, necrotic cells (Annexin V negative/PI positive); Q2, late apoptotic cells (Annexin V positive/PI positive); Q3, early-apoptotic cells (Annexin V positive/PI negative), and Q4, viable cells (Annexin V negative/PI negative).](fmicb-11-01172-g004){#F4}

The percentages of apoptotic HeLa cells exposed to 50 μM of HuscFv-bound 3O-C12-HSL (0.25, 0.5, 1.0, and 1.2 μM of individual HuscFvs) were significantly decreased compared with those without HuscFvs ([Table 2](#T2){ref-type="table"} and [Figure 5](#F5){ref-type="fig"}). The HuscFvs of all three *E. coli* clones could neutralize 3O-C12-HSL, leading to reduced HeLa-cell apoptosis.

###### 

Flow cytometric results evaluating the efficacy of HuscFvs using Annexin V-FITC/PI staining for 3O-C12-HSL-mediated cell apoptosis.

  HeLa cells treated with             Percent cellular apoptosis   Percent cellular survival
  ----------------------------------- ---------------------------- ---------------------------
  Medium alone                        6.77 ± 0.20                  92.50 ± 0.28
  3O-C12-HSL (50 μM)                  21.05 ± 2.23                 72.15 ± 1.91
  3O-C12-HSL + HuscFv-E44 (0.25 μM)   15.03 ± 0.49                 83.57 ± 0.50
  3O-C12-HSL + HuscFv-E44 (0.5 μM)    13.31 ± 0.12                 85.33 ± 0.25
  3O-C12-HSL + HuscFv-E44 (1.0 μM)    12.99 ± 0.41                 86.10 ± 0.35
  3O-C12-HSL + HuscFv-E44 (1.2 μM)    11.74 ± 0.66                 87.30 ± 0.70
  3O-C12-HSL + HuscFv-F15 (0.25 μM)   16.04 ± 1.06                 82.07 ± 1.20
  3O-C12-HSL + HuscFv-F15 (0.5 μM)    12.31 ± 0.49                 85.97 ± 0.50
  3O-C12-HSL + HuscFv-F15 (1.0 μM)    12.88 ± 0.75                 86.27 ± 0.75
  3O-C12-HSL + HuscFv-F15 (1.2 μM)    12.88 ± 0.48                 85.53 ± 0.47
  3O-C12-HSL + HuscFv-F19 (0.25 μM)   13.53 ± 0.46                 84.27 ± 0.49
  3O-C12-HSL + HuscFv-F19 (0.5 μM)    12.93 ± 0.18                 85.80 ± 0.17
  3O-C12-HSL + HuscFv-F19 (1.0 μM)    10.71 ± 0.60                 88.67 ± 0.64
  3O-C12-HSL + HuscFv-F19 (1.2 μM)    10.63 ± 0.91                 88.60 ± 0.87

![HuscFvs rescue HeLa cells from 3O-C12-HSL-mediated apoptosis. **(A)** The percentages of apoptotic cells of different treatment conditions, i.e., HeLa cells in medium alone, cells exposed to 50 μM 3O-C12-HSL (C12), cells added with 3O-C12-HSL mixed with various amounts of HuscFvs. **(B)** Density plots of flow cytometric analysis of doubly stained HeLa cells as in **(A)** (representative of one of the three reproducible experiments). The percent apoptotic cells caused by the 3O-C12-HSL was reduced significantly in the presence of HuscFvs.](fmicb-11-01172-g005){#F5}

HuscFv-bound-C12-HSL Had Reduced Ability to Induce sub-G1 Arrest of HeLa Cells {#S3.SS6}
------------------------------------------------------------------------------

Exposure of HeLa cells with 50 μM 3O-C12-HSL for 18 h resulted in 3.79 ± 0.52% of apoptotic cells in the hypodiploid DNA peak (sub-G1 population, which were apoptotic cells) as determined by flow cytometric analysis of the PI-stained cellular DNA. The numbers of cells with a hypodiploid DNA peak induced by the 3O-C12-HSL bound by the HuscFv-E44, HuscFv-F15, and HuscFv-F19, were decreased to 2.58 ± 0.10, 2.71 ± 0.10, and 1.79 ± 0.11%, respectively. The cells in medium alone had 1.04 ± 0.04% apoptotic cells ([Figure 6](#F6){ref-type="fig"}). The results of the sub-G0/G1 analysis were conformed to those of the Annexin V/PI binding assay data.

![Reduction of sub-G1 arrest population of 3O-C12-HSL-exposed cells by HuscFvs. **(A)** Percent sub-G1 population (mean ± SD of triplicate individual experiments) after different treatments. **(B)** Histograms of cell cycle distribution. The percentage of apoptotic cells in the hypodiploid DNA peak (sub-G1 population) of each treatment is indicated in each plot.](fmicb-11-01172-g006){#F6}

Degrees of Nuclear Damage Mediated by HuscFv-bound 3O-C12-HSL {#S3.SS7}
-------------------------------------------------------------

DAPI staining and confocal microscopy were used to observe the intact HeLa nuclei and nuclear DNA damage induced by the 3O-C12-HSL and the HuscFv-bound 3O-C12-HSL ([Figure 7](#F7){ref-type="fig"}). Intact nuclei of normal HeLa cells were stained weakly by the dye ([Figure 7A](#F7){ref-type="fig"}), while the fragmented nuclei of the 3O-C12-HSL-exposed cells were stained brightly ([Figure 7B](#F7){ref-type="fig"}). Damage to the nuclear DNA was reduced in cells exposed to HuscFv-F19-bound 3O-C12-HSL, as shown by the dimly stained nuclei ([Figure 7C](#F7){ref-type="fig"}).

![Appearances of DAPI stained-nuclei of HeLa cells after treatment with **(A)** Medium alone **(B)** 3O-C12-HSL (50 μM) and **(C)** mixture of 3O-C12-HSL (50 μM) and HuscFv-F19 (2 μM) for 18 h (original magnification 200×).](fmicb-11-01172-g007){#F7}

Mitigation of the 3O-C12-HSL Induced-mitochondrial Injuries by HuscFvs {#S3.SS8}
----------------------------------------------------------------------

Transmission electron microscopy was used to study mitochondrial changes of the HeLa cells after exposure to the 3O-C12-HSL and HuscFv-bound 3O-C12-HSL, using the cells in medium alone as a normal control. As shown in [Figures 8A,B](#F8){ref-type="fig"}, the mitochondria of the normal cells revealed an intact mitochondrial subcellular structure. In contrast, mitochondria of the cells treated with 50 μM of 3O-C12-HSL for 18 h exhibited a swollen appearance, with single or multiple distensions of the intercellular matrix in association with severe loss of cristae and double membranes ([Figures 8C,D](#F8){ref-type="fig"}). The pathological changes of the mitochondria were ameliorated in the cells exposed to HuscFv-F19-bound 3O-C12-HSL (representative), i.e., mild mitochondrial swelling and more cristae ([Figures 8E,F](#F8){ref-type="fig"}), compared with the 3O-C12-HSL-exposed cells.

![Transmission electron micrographs of mitochondrial ultrastructure. **(A,B)** normal mitochondria of HeLa cells. **(C,D)** HeLa cells treated with 3O-C12-HSL (50 μM). **(E,F)** HeLa cells treated with a mixture of 50 μM 3O-C12-HSL and 2 μM HuscFv-F19. Black arrows indicate mitochondria of the HeLa cells. Mitochondria of the cells exposed to the 3O-C12-HSL were swollen, characterized by a size increment with decreased electron density of the crista-free matrix.](fmicb-11-01172-g008){#F8}

Discussion {#S4}
==========

*Pseudomonas aeruginosa* 3O-C12-HSL not only regulates virulence factors of the bacteria, but also causes inflammation in the infecting host by the induction of pro-inflammatory cytokine and chemokine synthesis ([@B64]). The 3O-C12-HSL killed mammalian cells through programmed cell death, i.e., an apoptotic mechanism at concentrations ranging from 10 to 100 μM by rapidly triggering depolarization of mitochondrial membrane potential and release of cytochrome *c* into cytosol, which activates the caspase cascades ([@B66]; [@B71]; [@B29]; [@B59]; [@B68], [@B69]). The apoptotic cells manifest mitochondrial permeability transition (MPT), caspase activation, nuclear fragmentation, phosphatidylserine externalization, and cell shrinkage with apoptotic bodies ([@B77]; [@B6]). Mitochondrial swelling, depolarization, and membrane permeability are the key markers of the MPT that indicates mitochondria-stimulated programmed cell death in the pathogenesis of several diseases. Upon response to external stimuli or oxidative stress, the cells undergo continuous opening of permeability transition pores (PTP) in the mitochondrial inner membrane, which augments colloidal osmotic pressure in the matrix together with mitochondrial membrane depolarization, resulting in mitochondrial swelling ([@B5]) followed by rupture of the mitochondrial outer membrane and release of cytochrome *c* into the cytosol and activation of caspase cascades ([@B48]). The stimulated caspase-3 activates endogenous endonuclease, which cleaves nuclear DNA ([@B80]). Cells with apoptotic fragmented DNA or sub-G1 population are used as a marker of apoptosis ([@B53]). In this study, 3O-C12-HSL produced a significant dose-dependent increment in mammalian cell death by inducing apoptosis, which validates previous notions on the cytotoxicity of *P. aeruginosa* QS substance.

Deletion of *lasI* or *lasI* and *rhlI* diminished the lung-colonization ability of *P. aeruginosa* in a mouse model of acute pneumonitis ([@B64]). *P. aeruginosa* mutants with defective QS are known to have less virulence and be more susceptible to antibiotic treatments and host immunity than the respective wild-type ([@B18]). As such, *P. aeruginosa* QS systems are attractive targets for direct-acting therapeutic agents, of which the expected treatment consequences are mitigation of the severity of the bacteria-associated diseases ([@B47]). During the past decades, several groups of *P. aeruginosa* QS inhibitors/modulators have been identified: small chemical molecules, i.e., AHL analogs (phenylpropionyl homoserine lactones and phenyloxyacetyl homoserine lactones of the *N*-aryl homoserine lactone library) ([@B14]), *N*-acyl cyclopentylamides ([@B19]), halogenated furanone compound ([@B17]), other furanone derivatives ([@B27]), aspirin ([@B11]), and itaconimides and citraconimides ([@B12]); and natural inhibitors, such as secondary metabolites of the Australian marine macroalgae, *Delisea pulchra* ([@B15]), patulin and penicillic acid from extracts of *Penicillium* species ([@B52]), an organosulfur compound found in garlic extracts, named Ajoene ([@B21]), and derivatives of ellagic acid (dilactone of hexahydroxydiphenic acid) from black or chebulic myrobalan, *Terminalia chebula* Retz ([@B58]). Unfortunately, these compounds are relatively toxic to mammalian cells, which limits their therapeutic use ([@B41]). Recently, natural plant-derived compounds, *trans*-cinnamaldehyde (CA), and salicylic acid (SA) have been shown to effectively downregulate both *las* and *rhl* QS systems, reduce the production of extracellular virulence factors, i.e., protease, elastase, and pyocyanin, and reduce biofilm formation, concomitantly with repressed rhamnolipid gene expression ([@B2]). However, the sole use of QS inhibitors at high concentrations to eradicate bacterial infection completely is of legitimate concern due to potential toxicity ([@B61]).

Passive immunization has been used as an intervention for post-exposure morbidity and/or treatment of diseases since the late 18th century ([@B26]). An antibody molecule uses multiple amino acid residues in several CDRs (sometimes with the help of FRs) to form multiple non-covalent bonds with the target molecule, thus, making it difficult for pathogens to create antibody escape mutants, compared with small molecular drugs/inhibitors, from which resistant variants emerge rather easily and frequently. Therapeutic antibodies may be in the form of intact molecules (two antigen-binding sites with Fc fragment- when the bioactivities of the Fc are required for effectiveness) or merely smaller antibody fragments, i.e., F(ab′)~2~, Fab, scFv, or single domain (VH, V~H~H) with higher tissue penetrating ability than the intact four-chain counterpart when the Fc is dispensable. For *P. aeruginosa* infection, specific murine mAb, RS2-1G9, directed toward bacterial 3O-C12-HSL has been generated for use as an immunotherapeutic agent ([@B25], [@B24]). This murine antibody displayed the cytoprotective effect of 3O-C12-HSL-exposed host cells ([@B25], [@B24]; [@B7]). In addition, sheep-mouse chimeric mAb recognized native AHL protected mice from lethal *P. aeruginosa* infection ([@B44]). Nevertheless, while these 3O-C12-HSL-specific antibodies have therapeutic potential, their immunogenicity in human recipients, with possible adverse consequences, such as serum sickness, should be of concern.

Nowadays, any engineered fully human antibody format can be generated *in vitro* using phage display technology, invented by Nobel laureate, George Pearson Smith ([@B63]) as a biological tool ([@B57]). The target antigens, such as proteins or peptides, attached to a carrier surface, e.g., fixed cell, plastic bead, or well of an ELISA plate, can be used as bait to fish out phage clones that display recombinant antibodies binding to the antigen from an antibody phage display library ([@B31]). Suppressor *E. coli*, such as strain HB2151 transfected with antigen-bound phages, when grown in appropriate conditioned medium, produces antigen-specific antibodies, and these antibodies can be isolated from the bacterial lysate/homogenate ([@B16]; [@B57]). Nevertheless, attachment of the small molecular haptens, like 3O-C12-HSL, to solid surfaces (as well as retaining the native configuration of the molecule) for conventional phage biopanning, is a relatively complicated process compared with proteins or peptides. Therefore, in this study, an alternative method was used to produce fully human scFvs (HuscFvs) to the synthetic *P. aeruginosa* 3O-C12-HSL based on the principle of antibody polyspecificity and antigenic molecular mimicry, i.e., completely unrelated molecules can share common receptors, possibly through similar structural and/or chemical features involved in recognition and binding ([@B76]; [@B70]). A repertoire of *E. coli* clones carrying recombinant *huscfv*-phagemids was previously retrieved from a HuscFv phage display library ([@B31]) by panning with *P. aeruginosa* exotoxin A ([@B57]). Moreover, because the previously produced murine mAb, RS2-1G9, has been known as the *P. aeruginosa* quorum quencher, we used computerized antibody structure superimposition to select the bacterial derived-HuscFvs that shared structural homology with the murine mAb RS2-1G9 antigen-binding site. Using this method, the HuscFvs of three phagemid-transformed *E. coli* clones (E44, F15, and F19) showed high and satisfactory degrees of molecular similarity to the mAb RS2-1G9 antigen-binding site. Besides, these HuscFvs could neutralize the cytotoxic effects of the 3O-C12-HSL in the induction of cellular apoptosis. The HuscFv bound-3O-C12-HSL had a reduced capacity to mediate mitochondrial swelling, diminishing DNA damage and reducing sub-G1 arrest population of exposed cells. Unfortunately, the amount of C12-HSL inside the HeLa cells with and without HuscFv treatments were not measured; therefore, it is not known whether the HuscFvs could prevent HSL from entering the cells. Although the actual 3O-C12-HSL neutralizing mechanism of the HuscFvs needs laboratory investigation, the predicted structural complexes between the QS (ligand) and the HuScFvs (receptors) indicated that the latter used several residues in different CDRs and FRs to interact non-covalently with the target, including van der Waals' forces, hydrophobic interactions, and hydrogen bonds. These interactions might render the disarming of the bacterial toxic molecule through C12-HSL signal interference, which would mitigate bacterial disease severity. This perspective needs further testing of the HuscFvs on *P. aeruginosa* phenotypes both *in vitro* (bacterial culture), such as expression of the QS controlled virulence factors, as well as in the *in vivo* model of bacterial infection.

Conclusion {#S5}
==========

The engineered human single-chain variable fragments that attenuated the potent cytotoxicity of the *P. aeruginosa* quorum sensing molecule, 3O-C12-HSL, were generated successfully through the molecular basis of antibody polyspecificity and antigenic mimicry. The fully human antibody fragments rescued mammalian cells from the 3O-C12-HSL-mediated mitochondrial injuries, DNA damage, and cellular apoptosis *in vitro*. They should be tested further by step-by-step *in vivo* toward the clinical application as a sole or an adjunct therapy for the failing antibiotic treatment of *P. aeruginosa* infections.
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